Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
52°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
All News
Headline News
Benzinga
Chartmill
The Motley Fool
InvestorPlace
Investor's Business Daily
MarketBeat
Talk Markets
Press Releases
24-7 Press Release
AB Newswire
ACCESSWIRE
ACN Newswire
Authority Press Wire
Binary News Network
Brandpoint
Business Wire
CannabisNewsWire
CryptoCurrencyWire
Equities.com
eTrendy Stock
EZ Newswire
FinancialNewsMedia
Get News
getfeatured.news
GlobePRwire
Globe NewsWire
InvestorBrandNetwork
JCN Newswire
Law Firm Newswire
MediaOutReach
MerxWire
News Direct
Newsfile
NewsUSA
Newswire.com
Newsworthy.ai
Press Advantage
Press Release Distribution Service
PressConnect.ai
PressReach
PRLeap
PRLog
Prodigy
ReleaseWire
Small Business Trendsetters
Send2Press
StatePoint
Syndication Cloud
TheNewswire
Zexprwire
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
99
100
Next >
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
September 30, 2024
From
Merus N.V.
Via
GlobeNewswire
Tickers
MRUS
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
September 30, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Avalyn Announces Upcoming Presentations on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the 22nd International Colloquium on Lung and Airway Fibrosis
September 30, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Matthews International Completes Senior Notes Offering
September 30, 2024
From
Matthews International Corporation
Via
GlobeNewswire
Tickers
MATW
BDev Ventures Announces Strategic Investment in Personal AI
September 30, 2024
From
BDev Ventures LLC
Via
GlobeNewswire
LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
September 30, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LENZ
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease
September 30, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
Tickers
INMB
Aligos Therapeutics to Present at Investor Conferences in October
September 30, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Tickers
ALGS
Epilepsy Foundation Awards $200,000 at 12th Annual Shark Tank Competition
September 30, 2024
From
Epilepsy Foundation
Via
GlobeNewswire
Superluminal Medicines Announces Formation of Scientific Advisory Board
September 30, 2024
From
Superluminal Medicines Inc.
Via
GlobeNewswire
Shoals Technologies Group Appoints Chief Operations Officer and Interim Chief Legal Officer
September 30, 2024
From
Shoals Technologies Group
Via
GlobeNewswire
Tickers
SHLS
Nano Hearing Aids® Launches New Innovative "Completely in Canal" Hearing Aids
September 30, 2024
From
Nano Hearing Aids
Via
GlobeNewswire
The Future is Now: Confronting Today’s Healthcare Challenges and Shaping Tomorrow’s Care at Empower
September 30, 2024
From
Inovalon Holdings, Inc.
Via
GlobeNewswire
Adaptive Research Announces it has Begun Enrolling Patients in AriBio’s Phase 3 POLARIS-AD Clinical Trial
September 30, 2024
From
Adaptive Research Inc
Via
GlobeNewswire
AMN Healthcare to Hold Third Quarter 2024 Earnings Conference Call on Thursday, November 7, 2024
September 30, 2024
From
AMN Healthcare Services Inc
Via
GlobeNewswire
Tickers
AMN
Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study
September 30, 2024
From
Helius Medical Technologies, Inc.
Via
GlobeNewswire
Tickers
HSDT
Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024
September 30, 2024
From
Biora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
BIOR
The Oncology Institute of Hope & Innovation Launches Oregon Market
September 30, 2024
From
Toi Management, LLC
Via
GlobeNewswire
Tickers
TOI
TOIIW
Mattermost Appoints Matthew Heideman as Vice President of Public Sector to Lead Federal Growth Initiatives
September 30, 2024
From
Mattermost
Via
GlobeNewswire
Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities
September 30, 2024
From
Scorpius Holdings, Inc.
Via
GlobeNewswire
Wellinks Acquires Spire Health Creating Industry Leader in Predictive Patient Care for Cardiopulmonary Health
September 30, 2024
From
Wellinks Inc.
Via
GlobeNewswire
Osisko Announces Agreement to Purchase Royalties on Spartan Resources’ Dalgaranga Gold Project in Western Australia
September 30, 2024
From
Osisko Gold Royalties Ltd.
Via
GlobeNewswire
Tickers
OR
TSX:OR
Sascha Pallenberg and Rikesh Shah headline the Tomorrow.Mobility congress
September 30, 2024
From
Fira De Barcelona
Via
GlobeNewswire
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
September 30, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Tickers
ASX
ATHE
BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
September 30, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Tickers
BBIO
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
September 30, 2024
From
Traws Pharma, Inc.
Via
GlobeNewswire
Tickers
TRAW
BrightSpring Health Services, Inc. Welcomes Dr. Steve Miller to Board of Directors
September 30, 2024
From
BrightSpring Health Services, Inc.
Via
GlobeNewswire
Tickers
BTSG
Adeia to Present at Upcoming Conferences on Hybrid Bonding Technology
September 30, 2024
From
Adeia Inc.
Via
GlobeNewswire
Tickers
ADEA
Parsons to Announce Third Quarter 2024 Financial Results on October 30, 2024
September 30, 2024
From
Parsons Services Company
Via
GlobeNewswire
Tickers
PSN
Dr. Alejandro Duarte joins SEDA Expert’s Risk Management and Algorithmic Trading Expert Witness Practice
September 30, 2024
From
SEDA EXPERTS
Via
GlobeNewswire
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.